Filing Flows › Xtant Medical Holdings (XTNT) › Q2 2026
Xtant Medical Holdings (XTNT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Xtant Medical Holdings (XTNT) reported revenue of $23.0M for the second quarter 2026 (Q2 2026), -35% from a year earlier and +10% from the quarter before. Operating margin was -39.8%, net loss $9.4M (40.9% of revenue).
Xtant Medical Holdings, Q2 2026: revenue $23.0M (-35% year over year), operating margin -39.8%, net loss $9.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.0M | +10% | -35% |
| Operating profit | −$9.2M | — | -298% |
| Net earnings | −$9.4M | — | -365% |
| Operating cash flow | −$7.3M | — | -673% |
What changed
Revenue was $23.0M in Q2 2026, down 35% year over year and up 10% from the previous quarter. Orthobiologics was the largest line at 75% of revenue. Spinal Implant lost $5.4M year over year (down 49%), 44% of the total change.
Gross margin was 57.9%, down 10.7 points from Q2 2025. Operating costs exceeded revenue by $9.2M, an operating margin of -39.8%. Operating expenses grew 14% against a revenue fall of 35%. The fastest-growing cost line was Research & development (+23%). The quarter ended with a net loss of $9.4M, wider than the previous quarter's $3.1M loss.
Operating cash flow was −$7.3M. Non-cash charges added back $508K of depreciation and amortization and $875K of share-based compensation. Working capital and other items added $722K. Capital expenditures of $247K exceeded it, leaving free cash flow of −$7.6M.
Questions
What was Xtant Medical Holdings' revenue in the second quarter 2026?
Xtant Medical Holdings (XTNT) reported revenue of $23.0M for the second quarter 2026 (Q2 2026), -35% from a year earlier and +10% from the quarter before.
Was Xtant Medical Holdings profitable in the second quarter 2026?
Operating loss was $9.2M (-39.8% of revenue) and net loss $9.4M.